Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK10 | P53779 | 7/20 | 0.49 |
| ▸ | JUN | P05412 | 2/20 | 0.49 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.46 |
| ▸ | JAK2 | O60674 | 2/20 | 0.45 |
| ▸ | JAK1 | P23458 | 2/20 | 0.45 |
| ▸ | TYK2 | P29597 | 2/20 | 0.45 |
| ▸ | JAK3 | P52333 | 2/20 | 0.45 |
| ▸ | MAPK8 | P45983 | 7/20 | 0.42 |
| ▸ | MAPK9 | P45984 | 5/20 | 0.42 |
| ▸ | MCHR1 | Q99705 | 4/20 | 0.42 |
| ▸ | CDK1 | P06493 | 2/20 | 0.39 |
| ▸ | CDK4 | P11802 | 1/20 | 0.39 |
| ▸ | CCND1 | P24385 | 1/20 | 0.39 |
| ▸ | CDK2 | P24941 | 1/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL558928 | 1.00 | MAPK10 (0.49) | MAPK10JUNTNIKJAK2JAK1 | |
| SCHEMBL10166326 | 1.00 | MAPK10 (0.49) | MAPK10JUNTNIKJAK2JAK1 | |
| SCHEMBL559322 | 0.88 | MAPK10 (0.53) | MAPK10JUNTNIKJAK2JAK1 | |
| SCHEMBL10166333 | 0.88 | MAPK10 (0.53) | MAPK10JUNTNIKJAK2JAK1 | |
| SCHEMBL559321 | 0.88 | MAPK10 (0.53) | MAPK10JUNTNIKJAK2JAK1 | |
| SCHEMBL558422 | 0.87 | MAPK10 (0.53) | MAPK10JUNTNIKJAK2JAK1 | |
| SCHEMBL558421 | 0.87 | MAPK10 (0.53) | MAPK10JUNTNIKJAK2JAK1 | |
| SCHEMBL558890 | 0.82 | TNIK (0.56) | MAPK10JUNTNIKJAK2JAK1 | |
| SCHEMBL558889 | 0.82 | TNIK (0.56) | MAPK10JUNTNIKJAK2JAK1 | |
| SCHEMBL558834 | 0.81 | ROCK2 (0.43) | MAPK10JUNTNIKJAK2JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120035194-A1 | SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS | PFIZER INC. (US) | 2012-02-09 | — | — | US | disclosed |
| US-7998978-B2 | Substituted 2-amino-fused heterocyclic compounds | PFIZER INC. (US) | 2011-08-16 | — | — | US | disclosed |
| US-20100056506-A1 | SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2010-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035194-A1 | SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS | MAPK1, SLC5A1, ATF1 | MAPK10 32/4885JUN 36/4885TNIK 1616/4885 |
| US-20100056506-A1 | SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS | MAPK1, SLC5A1, ATF1 | MAPK10 32/4885JUN 36/4885TNIK 1616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.